Allianz Holds at 418 Euros as Jefferies Trims Its Target Gap and Management Ranks Turn Over
Published on 10/10/2026 at 12:40 | Editorial boerse-global.de
Allianz shares finished Friday's session at 418.00 euros, a modest gain of 0.4 percent that left the Munich insurer roughly 8.0 percent below its 52-week high of 454.50 euros. The stock's recent soft patch has coincided with the expiry of its previous share buyback programme, according to media reports, though that timing is not treated as the sole explanation for the pullback.
Jefferies Raises Target, Keeps Rating
Analyst Philip Kett of Jefferies adjusted his view on the stock, lifting the price target from 420 to 440 euros while reaffirming a "Hold" rating. The revision rests on the accelerated reinvestment of realised proceeds from Allianz's Indian joint venture into fixed-income securities, a move framed against persistent volatility in the bond market. The higher target does not amount to an upgrade, and the unchanged recommendation caps how much signal investors should read into it. Friday's close of 418.00 euros sits below the new 440-euro mark, a comparison that helps position the valuation without establishing any causal link between the analyst action and the share price.
Leadership Changes Across Several Units
Behind the headline numbers, the group is pressing ahead with a broad reshuffle of its core subsidiaries ahead of upcoming quarterly figures. Sören Kupke will take charge of the sales division on the board of Allianz Lebensversicherungs-AG and the broker sales remit at Allianz Private Krankenversicherungs-AG on 1 January 2027. He succeeds Thomas Wiesemann, who steps down from both bodies on 31 December 2026.
Elsewhere in the group, Philipp Kroetz is set to become chief executive of Allianz Partners on 1 November 2026, taking over from Tomas Kunzmann, while Laurent Floquet will lead Allianz Direct. Kunzmann is slated to join the board of Allianz SE on 1 January 2027. All of these appointments remain subject to the customary approval of supervisory authorities. They represent organisational changes rather than any demonstrated improvement in business performance.
Should investors sell immediately? Or is it worth buying Allianz?
On the product side, Allianz Private Krankenversicherungs-AG launched its "MeinKrankenhausschutz" tariff earlier this month. The offering spans three benefit tiers and allows certain existing customers to switch without a fresh health assessment.
Industrial Claims Study Draws a Wider Circle
Separately, Allianz Commercial examined 7,888 business interruption claims across the industrial insurance sector, arriving at a combined value of roughly 6.74 billion euros. The average claim came in above 850,000 euros. Covering the years 2021 to 2025, the study describes losses over an extended period rather than the outcome of any single financial year.
Scope matters here for anyone assessing the equity. The figures relate to the industrial insurance industry as a whole and should not be read as a burden borne exclusively by Allianz. The analysis quantifies the scale of the claims complex under review, not its direct effect on group profit.
Allianz at a turning point? This analysis reveals what investors need to know now.
What Comes Next
Clarity on operating earnings for the current financial year should arrive with the next scheduled reporting date. Allianz SE will publish its third-quarter 2026 results on 12 November. For now, three threads remain distinct: the personnel realignment, the industry-wide claims picture, and the valuation of the stock. The higher price target is a valuation signal; the unchanged recommendation limits how far that signal travels.
Ad
Allianz Stock: New Analysis - 10 October
Fresh Allianz information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
